Milford, Massachusetts (PRWEB) May 13, 2013
NITTO DENKO Avecia Inc., an industry leader in therapeutic nucleic acid manufacturing and development services, is proud to introduce a new pre-clinical oligonucleotide synthesis service, OliGrow. Combining phase appropriate quality and purity standards with a high level of customer service, the Avecia OliGrow team delivers pre-clinical oligonucleotides at µmol to mmol scales, with affordable pricing and fast turn around times.
OliGrow offers custom DNA and RNA with standard chemical modifications, along with advanced solutions for more specialized needs, including oligonucleotide conjugates and specialty amidites. Its experts operate within a dedicated facility at Avecia’s FDA- registered Cincinnati, OH plant, and use instrumentation, methods, and analytics designed for scalability and consistency throughout the development process.
As the only oligonucleotide CMO that can deliver both the first µmols of pre-clinical material and bring a program through to commercialization, Avecia OliGrow creates value for its customers by building compound knowledge from the very start, avoiding future surprises and costly technical transfers and process changes.
Dr. Marc Lemaitre, Avecia’s VP for New Businesses and Services, says the company is very proud to bring this small scale service under the same roof as the large scale, clinical productions. “Previous options to bridge the gap between pure research and clinical production in the oligo space were largely accomplished through collaborations and partnerships between multiple companies. But now are pleased to offer OliGrow as a unique, one- stop option for oligonucleotide developers.”
ABOUT NITTO DENKO Avecia Inc.
NITTO DENKO Avecia, Inc. is a drug development and manufacturing services company located in Milford, MA, and is a part of Nitto Denko Corporation, Japan’s leading diversified materials manufactu
Copyright©2012 Vocus, Inc.
All rights reserved